Abstract
The discovery that their neonatal diabetes is caused by gain-of-function mutations in the K(ATP) channel has enabled many patients to switch from insulin to oral sulphonylurea drugs. Here, I review molecular, physiological, and clinical features of this change in therapy.
2010 Elsevier Inc. All rights reserved.
MeSH terms
-
Animals
-
Diabetes Mellitus / congenital*
-
Diabetes Mellitus / drug therapy*
-
Diabetes Mellitus / genetics
-
Diabetes Mellitus / physiopathology
-
Diabetes Mellitus, Experimental / drug therapy
-
Diabetes Mellitus, Experimental / physiopathology
-
Humans
-
Infant, Newborn
-
Insulin / metabolism
-
Insulin / therapeutic use
-
KATP Channels / genetics*
-
KATP Channels / metabolism
-
Mice
-
Mutation*
-
Sulfonylurea Compounds / therapeutic use*
Substances
-
Insulin
-
KATP Channels
-
Sulfonylurea Compounds